Shares of CymaBay Therapeutics soared after the company announced the experimental primary biliary cholangitis (PBC) treatment seladelpar hit the mark in a Phase III study that sets up potential regulatory approval for this indication.
https://www.pharmalive.com/wp-content/uploads/2020/08/CymaBay-Therapeutics-PBC-Treatment-Hits-the-Mark-in-Phase-III-Study-BioSpace-8-3-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-08-03 21:27:572020-08-04 14:02:31CymaBay’s PBC Treatment Hits the Mark in Phase III Study